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Abstract
The pathophysiological mechanisms underlying fibromyalgia are still unknown, although some evidence points to
endogenous opioid dysfunction. We examined how endogenous opioid antagonism affects pain and mood for women with
and without fibromyalgia. Ten women with fibromyalgia and ten age- and gender-matched, healthy controls each attended
two laboratory sessions. Each participant received naltrexone (50mg) at one session, and placebo at the other session, in a
randomized and double-blind fashion. Participants were tested for changes in sensitivity to heat, cold, and mechanical pain.
Additionally, we collected measures of mood and opioid withdrawal symptoms during the laboratory sessions and at home
the night following each session. At baseline, the fibromyalgia group exhibited more somatic complaints, greater sensory
sensitivity, more opioid withdrawal somatic symptoms, and lower mechanical and cold pain-tolerance than did the healthy
control group. Neither group experienced changes in pain sensitivity due to naltrexone administration. Naltrexone did not
differentially affect self-reported withdrawal symptoms, or mood, in the fibromyalgia and control groups. Consistent with
prior research, there was no evidence found for abnormal endogenous opioid activity in women with fibromyalgia.
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Introduction
Fibromyalgia is a chronic and debilitating condition, charac-
terized primarily by diffuse musculoskeletal pain, mechanical
allodynia, and hyperesthesia [1]. Other symptoms–including sleep
disturbance, fatigue, anxiety, depression, and cognitive impair-
ment–further contribute to its severity [2,3]. Fibromyalgia affects
approximately 5% of women [4] and 1.6% of men [5] in the
general U.S. population, many of whom still need effective
treatment options [6]. The condition significantly impacts the
quality of life for affected individuals [7] and imposes a large
economic burden on society [8].
Recent studies of fibromyalgia pathophysiology point to central
nervous system dysregulations [9]. One central nervous system
target of investigation has been endogenous pain modulators
[10,11] such as opioid-peptides [12]. We focused on beta-
endorphin, which is an important mediator of analgesia [13].
Previous studies that contrasted peptide concentrations in
fibromyalgia and control groups found no differences in
cerebrospinal fluid [14] or blood plasma [15,16]. However, one
study identified lower concentrations of beta-endorphins in the
peripheral blood mononuclear cells of fibromyalgia patients [17].
A recent study also found decreased mu-opioid receptor
availability in the brains of fibromyalgia patients [18]. Despite
the indications of altered mu-opioid systems, three studies
employing an experimental design and the (predominantly mu-)
opioid receptor antagonist naloxone failed to find any significant
effect in fibromyalgia. Two of those studies found that naloxone
did not affect pain sensitivity [19,20], and the third concluded that
naloxone’s effects are similar to those of a placebo [21].
To help address the conflicting information in the literature
regarding endogenous opioid peptide involvement in fibromyalgia
pathophysiology, we conducted this study on the effects of opioid
antagonismin fibromyalgia pain and mood symptoms. Weexamined
two competing hypotheses of how groups might differ in their responses
to naltrexone. In Hypothesis 1, we predicted that women with
fibromyalgia would be lessaffected by naltrexone administration than
healthy controls (as represented by smaller increases of pain sensitivity
and negative mood under naltrexone). Hypothesis 1 corresponds with
the view that women with fibromyalgia have deficient endogenous
pain inhibition. In the competing Hypothesis 2, we predicted that
women with fibromyalgia would show exaggerated increased pain
sensitivity and negative mood when given naltrexone, as compared to
healthy controls. Hypothesis 2 represents the view that although
opioid-based pain systems are maximally engaged in fibromyalgia,
they insufficiently attenuate pain [22].
Methods
Study overview
In our study, women with and without a diagnosis of
fibromyalgia attended two laboratory sessions, which were held
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naltrexone in one session, and placebo in the other. Drug
administration was randomized and double-blinded. In each
laboratory session, tests of pain sensitivity were administered, as
well as measures of mood and opioid withdrawal. We extended
others’ experimental drug methodology [19,21] in a few important
ways: 1) Both physical and psychological manifestations of
fibromyalgia were measured. 2) The more potent opioid receptor
antagonist naltrexone was used instead of naloxone. 3) Symptoms
directly associated with opioid withdrawal were recorded. 4)
Multiple pain modalities were used, including heat, cold and
mechanical. 5) Home measurements were collected on some
variables the night following each laboratory session.
Participants
Participants were 10 women with fibromyalgia and 10 healthy
controls matched for gender, age, and income, whose average age
was 55 years (SD=7.7). Most of the participants were Caucasian
(85%); two were Hispanic, and one was African-American. The
average daily pain level for women with fibromyalgia was 6.1 on a
10-point scale (standard deviation of 2.4), a score that indicates
moderately-high disease severity. Subjects were recruited via flyers
or newspaper announcements in the greater metropolitan area of
Phoenix, Arizona. Inclusion criteria included: 1) 18 or more years
of age, 2) ability to give informed consent, and for the fibromyalgia
group, 3) a physician’s diagnosis of fibromyalgia. Exclusion criteria
were: 1) current or past use of opioid medications and 2)
pregnancy, or plans to become pregnant. All participants
completed an evaluation for fibromyalgia on their first study visit,
to confirm the physician diagnosis. Participants were fully
informed of all study procedures and the risks involved, and all
procedures were approved by the Institutional Review Board at
Arizona State University. Written consent was obtained at the first
laboratory visit.
In the fibromyalgia group, two women were taking prescription
medications for pain (celecoxib, cyclobenzaprine, and carisopro-
dol), two were taking antidepressant or anxiolytic drugs with
potential analgesic effects (trazadone and sertraline), and two were
taking sleep-aid medications as needed (eszopiclone and zolpi-
dem). One woman in the control group was taking an
antidepressant (paroxetine). Participants were allowed to continue
their medication throughout their participation in the study.
Measures
Baseline descriptive measures. To determine baseline
differences between the two groups, three measures were
completed before any capsules were administered: fibromyalgia
severity, general somatic complaints, and sensitivity to sensory
stimulation. In both groups, we administered the 10-item
Fibromyalgia Impact Questionnaire (FIQ; [23]) that measures
severity of fibromyalgia. The FIQ is a widely used scale with good
reliability and validity [24]. General somatic complaints were
measured with the Somatization and Emotional Contribution
Scale (SECS). The SECS is an author-generated, original somatic
symptom checklist of 42 commonly experienced physical
symptoms such as headache, muscle tension, and dizziness.
SECS exhibits good internal consistency (a=0.93) and construct
validity [25] with the Somatization sub-scale of the Symptom
Checklist-90R [26]. Sensitivity to sensory stimulation was assessed
with the Sensory Hypersensitivity Scale (SHS; [27]). The SHS a
25-item scale that can assess general sensitivity (internal reliability
of a=0.80) or modality-specific sensitivity (taste, light, sound,
smell, pain, heat, cold, texture, and allergies). For the present
analyses, we examined only the general sensitivity scores.
Naltrexone outcome measures. Drug response was
assessed via three quantitative sensory tests of pain. The three
pain tests were: 1) heat pain threshold and tolerance, 2) cold pain
threshold and tolerance, and 3) mechanical pain threshold. To
measure heat pain threshold and tolerance, a thermode was placed
on the thenar eminence of the hand and heated from a baseline
temperature of 32uC at a rate of 0.5uC/sec (maximum 50uC).
Participants indicated via pressing a button when the temperature
first became painful (threshold) and when the heat was no longer
bearable (tolerance), at which point the thermode immediately
cooled. Cold pain threshold and tolerance were measured
following a similar protocol to heat. The thermode was placed
on the thenar eminence of the opposite hand and cooled down
from 32uC at a rate of 0.5uC (minimum 0uC). Participants
indicated both pain threshold and tolerance levels. Mechanical
pain sensitivity was measured using the 18 sites defined by the
American College of Rheumatology [28]. Pressure was applied to
the sites using a Fischer dolorimeter (Pain Diagnostics, Great
Neck, NY) and 1 cm
2 rubber disk, at a rate of 1 kg/cm
2/s, until
the participant indicated pain. Pain threshold was recorded in kg/
cm
2, and all points were averaged to yield a total score of
mechanical pain threshold. Some studies have found mechanical
stimulation to be superior to thermal stimulation in predicting
clinical pain [29,30].
In addition to the pain tests, participants also completed two
self-reported questionnaires which examined opioid withdrawal
symptoms, positive mood, and negative mood. Withdrawal
symptoms were assessed with the Subjective Opiate Withdrawal
Scale (SOWS; [31]). The scale includes withdrawal symptoms
such as tremors, nausea, and perspiration. In our sample,
Cronbach’s a=0.87. Scores of positive and negative mood were
obtained using the Positive and Negative Affect Schedule
(PANAS); a widely used scale with strong psychometric properties
[32,33]. This twenty-item scale yields separate, largely uncorre-
lated scores for positive (e.g., ‘‘excited,’’ ‘‘strong,’’ ‘‘interested’’)
and negative (e.g., ‘‘nervous,’’ ‘‘irritable,’’ ‘‘upset’’) affect.
Materials and Equipment
The study drug was naltrexone, approved by the U.S. Food and
Drug Administration for treating narcotic dependency [34].
Naltrexone is an opioid-receptor antagonist with particular affinity
for mu-opioid receptors [35]. It is orally absorbed, reaches peak
plasma levels in approximately one hour, and has a half-life of
about 4 hours [36]. The drug is a competitive antagonist,
preventing active opioid molecules from docking at receptor sites.
The major biologically active metabolite is 6-b-naltrexol, which
has a half-life of from 12 to 18 hours [37]. In healthy volunteers,
naltrexone is not associated with any significant adverse events
[38,39]. Naltrexone has been employed successfully in pain studies
as an alternative to intravenously-administered naloxone [40].
Naltrexone and placebo capsules were compounded by the
Campus Health Service Pharmacy at Arizona State University.
Opaque gelatin capsules were filled with 50mg of naltrexo-
ne+190mg corn starch filler, or 240mg corn starch filler for
placebo. Weights were determined on an Acculab VIR Electronic
Balance with readability to 1mg and precision rated at 2mg.
Capsules were placed in prescription vials, labeled ‘‘A’’ and ‘‘B,’’
with the identity of each vial’s contents known only to the
pharmacy manager. All study personnel were blinded to the
contents of capsules. The identities of the capsules were revealed
by the pharmacy manager at the conclusion of the study.
Hot and cold stimuli were presented with a Medoc TSA-II
(Medoc Advanced Medical Systems; Durham, NC) and Peltier-
type, 30630mm thermode. The TSA-II allows for rapid heating
Naltrexone and Fibromyalgia
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peripheral device allowed participants to indicate when threshold
or tolerance levels had been reached.
Procedures
All procedures were carried out at the Community Health
Services Clinic at ASU by research personnel blinded to the
gelcaps’ contents. Figure 1 shows the order of study procedures.
Upon arrival and consenting, participants completed the baseline
descriptive scales (visit #1 only), the mechanical pain test, and the
SOWS and PANAS. Naltrexone or placebo was then orally
administered by a research assistant, who then started a timer to
run for one hour and 45 minutes. Drug randomization was
performed using a computerized, random assignment generator.
The delay before primary assessments allowed sufficient absorp-
tion of the drug. During the interim period, participants were
trained on the thermal stimulator, and they underwent practice
versions of all the tests. For the remainder of the time, participants
were kept on the premises and allowed to read.
After the waiting period, participants underwent the three
quantitative sensory tests for pain: heat pain threshold and
tolerance, cold pain threshold and tolerance, and a second
mechanical threshold. Each participant then completed the self-
reported PANAS and SOWS, received $50.00, and was sent home
with the instructions to complete an additional PANAS and
SOWS, 7–8 hours after leaving the lab.
Statistical analysis
We used SPSS version 17 to conduct all hypotheses tests. To
compare fibromyalgia and control groups on the baseline
measures, we used simple between-group (independent) t-tests.
For all other tests (heat pain, cold pain, mechanical pain,
withdrawal symptoms, and mood), we used linear mixed models.
Subject ID was included as a random effect, and an unstructured
covariance type was used for all analyses. Group (fibromyalgia
versus control) and drug (naltrexone versus placebo) were included
as fixed effects. For measures taken at multiple times throughout
the day, time was included as an additional fixed effect.
Results
Two individuals with a physician diagnosis of fibromyalgia did
not meet the American College of Rheumatology [28] criteria for
mechanical sensitivity, and were excluded from all analyses. The
remaining 8 fibromyalgia participants all had an average daily
pain level of at least 5 (on a 10-point scale). All fibromyalgia
participants met widespread pain conditions (pain above and
below waist, on both sides of the body, and in the axial skeletal
region). No individuals in the control group met criteria for
fibromyalgia. Independent sample t-tests revealed that the
fibromyalgia group had higher FIQ scores than healthy controls
(47.3 versus 10.5; t(16)=7.6, p ,.001), as well as more positive
tender points (14.9 versus 1.1; t(16)=11.1, p,.001), more general
somatic complaints (1.5 versus 0.7, t(16)=3.4, p=.004) and
greater sensory sensitivity (3.3 versus 2.4; t(16)=4.2, p=.001).
The effects of drug (naltrexone versus placebo) and group
(fibromyalgia versus control) were tested on the three quantitative
sensory tasks (see Table 1 for all means and standard deviations).
Figure 1. Flow diagram of study procedures. Study procedures
conducted on each participant, once with naltrexone, and once with
placebo. SOWS=Subjective Opioid Withdrawal Scale; PANAS=Positive
and Negative Affect Schedule; QST=Quantitative Sensory Testing.
doi:10.1371/journal.pone.0005180.g001
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(F(1,16)=7.31, p=0.016), marginally lower heat pain tolerance
(F(1,16)=4.2, p=0.057), more sensitivity to cold pain onset
(F(1,16)=9.2, p=0.008), and less tolerance for cold pain
(F(1,16)=8.5, p=0.010). There were no main effects for drug,
nor any drug6group interactions for heat or cold pain tests. We
then tested the effects of naltrexone on mechanical pain sensitivity.
Fibromyalgia patients had significantly lower mechanical pain
thresholds than controls (F(1,16)=187.04, p,.0005). A significant
effect for drug emerged, with both groups showing increased
thresholds (i.e., decreased pain sensitivity) during the naltrexone
trial (F(1,16)=5.48, p=.032). However, there were no significant
interactions with group; fibromyalgia and control individuals
reacted similarly to the drug administration.
The effects of drug, group, and time (before capsule, 2 hours
after capsule, and 8 hours after capsule) were tested on the
following variables: opioid withdrawal symptoms, positive mood,
and negative mood. For opioid withdrawal symptoms (Figure 2), a
significant group effect was revealed (F(1,16)=24.4, p,0.0005),
with fibromyalgia patients reporting a significantly greater number
of withdrawal-type symptoms. There was also a significant effect
for time (F(1,16)=6.7, p=0.008), with symptoms increasing at the
final measurement period (approximately 8 hours after drug
administration). However, the drug6time interaction failed to
reach significance (F(1,16)=2.5, p=0.116). Furthermore, there
was no interaction between group and drug; patients and controls
reacted similarly to the naltrexone administration. For positive mood,
there was a significant drop over time (F(1,16)=17.58, p,.0005).
No other significant effects emerged. For negative mood, there were
no significant effects for group, drug, time, nor any interactions.
Discussion
In this study, we investigated the role of endogenous opioid
peptides in fibromyalgia pain sensitivity. Fibromyalgia participants
and age- and gender-matched controls showed similar responses to
naltrexone, a potent opioid antagonist. We found no evidence of
opioid dysregulation in fibromyalgia.
Baseline comparison between fibromyalgia and healthy
control groups
Many studies have identified elevated sensory, somatic and
psychological symptoms in those with fibromyalgia; greater
sensitivity to heat, cold, and mechanical pain [10], greater windup
pain [21], greater incidence of affective disorders [41], general
somatic complaints [42], cognitive impairment [43] and repro-
ductive and sleep issues [44]. Fibromyalgia often overlaps with
irritable bowel, chronic fatigue [45], and multiple chemical
sensitivity syndromes [46]. Consistent with several previously
reported group differences, we identified several baseline group
differences. In addition to a self-reported higher sensitivity to a
range of stimuli, and a greater number of somatic complaints than
controls, fibromyalgia patients also had higher sensitivity to heat,
cold, and mechanical pain. The wide variety of stimuli to which
fibromyalgia individuals are sensitive suggests that a central
nervous system amplification of signals may underlie fibromyalgia
symptomotology [47,48].
Effects of naltrexone
Neither experimental hypothesis was supported by the results,
as both the fibromyalgia and control groups responded similarly to
naltrexone administration. Pain threshold and tolerance were not
affected by opioid antagonism in either group. Overall, our
findings agree with those from similar past experiments–fibromy-
algia pain does not appear to be related to beta-endorphin
dysregulation [19–21]. Interestingly, both groups experienced
significantly lower mechanical pain sensitivity on the naltrexone-
administration visit, contrasted with the placebo visit. Again, there
was no divergence in response between fibromyalgia and control
groups, further suggesting that the mu-opioid system is not a site of
dysregulation.
Both groups exhibited increased opioid withdrawal symptoms
over time. While Figure 2 suggests that this effect was most
Table 1. Drug and placebo means (SD) for all repeated-
measures tests in Fibromyalgia and healthy controls.
Fibromyalgia Healthy Control
Drug Placebo Drug Placebo
Heat threshold(uC) 41.4 (2.5) 41.6 (4.2) 44.2 (1.8) 44.3 (1.7)
Heat tolerance(uC) 44.8 (2.1) 45.2 (2.3) 46.5 (1.7) 46.7 (1.2)
Cold threshold (uC) 17.1 (5.7) 16.2 (7.3) 8.8 (6.6) 8.6 (4.6)
Cold tolerance(uC) 11.0 (5.4) 10.3 (6.8) 4.1 (4.2) 3.7 (4.3)
Pressure threshold (kg/cm2)
Pre drug 5.6 (0.9) 6.4 (1.1) 9.7 (0.3) 9.9 (0.2)
Post drug 5.7 (1.0) 6.1 (1.0) 9.7 (0.3) 9.8 (0.3)
Opioid withdrawal
Pre drug 19.5 (2.7) 20.1 (4.0) 15.7 (1.1) 16.0 (1.1)
Post drug 20.0 (3.7) 19.5 (3.8) 15.5 (1.1) 15.7 (0.8)
Home 23.1 (5.1) 20.1 (3.6) 17.4 (2.9) 15.9 (1.2)
Positive mood
Pre drug 2.4 (0.9) 2.8 (0.9) 2.6 (0.7) 2.5 (0.7)
Post drug 2.2 (1.0) 2.3 (1.1) 2.2 (0.7) 2.4 (0.7)
Home 2.2 (1.0) 1.8 (0.8) 1.9 (0.6) 1.8 (0.6)
Negative mood
Pre drug 1.3 (0.5) 1.2 (0.6) 1.0 (0.1) 1.0 (0.1)
Post drug 1.2 (0.2) 1.3 (0.6) 1.0 (0.0) 1.0 (0.2)
Home 1.5 (0.7) 1.3 (0.8) 1.3 (0.9) 1.0 (0.1)
doi:10.1371/journal.pone.0005180.t001
Figure 2. Effects of naltrexone on self-reported opioid
withdrawal symptoms. Self-reported opioid withdrawal symptoms
at 0 hours, 2 hours, and 8 hours (home measurement) after drug and
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withdrawal symptoms was not statistically significant. This
marginal effect may have been suppressed by a small sample size.
Even so, the two groups showed no differential response to
naltrexone. It is interesting that the effects of naltrexone may be
observed so long after administration. The delayed effect of
naltrexone has been previously reported [49], and may be due to
the extended half-life of the 6-b-naltrexol metabolite [50,51]. It is
unknown if naltrexone would have produced changes in pain
processing if measured at a later time-point.
Four methodological issues limit our interpretation of our
results. First, the small sample size may not have provided
adequate power for all tests. Observed effect sizes (mean standard
differences) for within-group naltrexone effects, however, were
very small, ranging from 0.05 to 0.19. Post-hoc power analyses
revealed that, with alpha of 0.05 and beta of 0.80, a minimum of
220 participants per group would be needed to detect a significant
effect. Therefore, for most tests, the nonsignificant findings were
likely not due to inadequate sample size. Second, we did not
collect information on menstrual phase, even though sensitivity to
experimental pain is known to vary with fluctuating sex hormones
[52]. The effect of menstrual phase was likely minimized as
sessions were conducted no more than 72 hours apart. Third,
participants’ medications may have affected results from some
tests. Our use of within-person statistics, and exclusion of those
taking opioid medications, mitigates the impact of medication use.
Fourth, only one dose of naltrexone was tested, and a larger dose
may have produced larger changes in the dependent variables. We
note, however, that 50mg is a typical dose for strongly blocking
mu-opioid receptors [39,53,54], and larger doses may do more to
extend the duration of action rather than increasing the
completeness of the blockade [55].
Several opportunities for future studies exist. Beta-endorphins
represent just one of a number of opioids, themselves a small part
of all pain-related peptides. Other components of the peptide
system of pain should be systematically investigated, including
other opioid-peptides such as met-enkephalin [56], algesic opioid
peptides such as nociceptin/orphanin FQ [57], nerve growth
factor [58], calcitonin gene related peptide, substance P [59], and
dynorphin A [60]. Further research may also utilize more sensitive
measurement techniques, such as temporal summation produced
by rapid heat taps.
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